Impact of medical therapy on patients with Crohn’s disease requiring surgical resection

Table 1 Demographic and surgical details for Crohn’s disease patients with first resections in years 1995-2000 (cohort A) and years 2005-2010 (cohort B)

	Cohort A 1995-2000 (n = 85)	Cohort B 2005-2010 (n = 114)	P value
Age	33 (± 12.1)	31.5 (±13.9)	0.440
Gender (M/F)	30.6 (26)/69.4 (59)	54.4 (62)/ 45.6 (52)	0.001
Montreal classification
Age at diagnosis (A1/A2/A3)	9.8%/74.4%/15.9%	21.1%/65.8%/13.2%	0.110
Disease behavior (B1/B2/B3)	38.8%/31.8%/29.4%	12.3%/45.6%/42.1%	< 0.0001
Disease location (L1/L2/L3)	32.9%/28.2%/38.8%	26.3%/14.9%/58.8%	0.010
Medication exposure
5-ASA	53.6 (45)	29.8 (34)	0.001
CS	69.1 (58)	75.4 (86)	0.320
IM	21.4 (18)	56.1 (64)	< 0.0001
Surgical details
Time from diagnosis to surgery (mo)	72 ± 83.8	72 ± 89.5	0.710
Amount of small bowel resected (cm)	21 ± 12.6	23 ± 17.5	0.820
Length of hospital stay (d)	10 ± 16.7	9 ± 8.0	0.050

Data are expressed as absolute numbers (percentage) or mean ± SD. 5-ASA: 5-aminosalysilic acid; CS: Corticosteroid; IM: Immunomodulator; M: Male; F: Female.

Table 2 Demographic and Surgical details for patients treated with and without anti-tumor necrosis factoragents in years 2005-2010 (cohort B)

	Anti-TNF (n = 38)	Without Anti-TNF (n = 76)	P value
Age	29.5 (± 13.14)	33.5 (± 14.05)	0.10
Gender (M/F)	60.5 (23)/39.5 (15)	51.3 (39)/48.7 (37)	0.35
Smoking status (yes)	26.3 (10)	23.7 (18)	0.82
Montreal classification
Age at diagnosis (A1/A2/A3)	39.5%/50%/10.5%	11.8%/73.7%/14.5%	0.003
Disease behavior (B1/B2/B3)	18.4%/39.5%/42.1%	9.2%/48.7%/42.1%	0.33
Disease location (L1/L2/L3)	23.7%/29%/47.4%	27.6%/7.9%/64.5%	0.01
Medication exposure
5-ASA	29 (11)	30.3 (23)	0.88
CS	81.6 (31)	72.4 (55)	0.28
IM	79 (30)	44.7 (34)	0.001
Surgical details
Time from diagnosis to surgery (mo)	90 ± 63.1	48 ± 100.2	0.02
Amount of small bowel resected (cm)	23 ± 12.4	21.5 ± 19.3	0.92
Length of hospital stay (d)	9 ± 8.6	10 ± 7.7	0.76

Data are expressed as absolute numbers (percentage) or mean ± SD. 5-ASA: 5-aminosalysilic acid; CS: Corticosteroid; IM: Immunomodulator; M: Male; F: Female.